Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy

Hidenobu Ishii, Koichi Azuma, Kazuhiko Yamada, Norikazu Matsuo, Masayuki Nakamura, Takaaki Tokito, Takashi Kinoshi, Tomoaki Hoshino


INTRODUCTION

Non-small-cell lung cancer (NSCLC) is the leading cause of death worldwide due to cancer. Transbronchial biopsy (TBB) using a flexible bronchoscope has been commonly used for establishing a diagnosis of lung cancer, having a more favourable safety profile than transthoracic needle aspiration or surgical procedures. Although the diagnostic yield of TBB has not been satisfactory, especially for small peripheral lesions, recent technical advances have improved its diagnostic accuracy. Therapeutic strategies for NSCLC over the past few decades have focused on overcoming resistance to molecular targeted therapies and development of immunotherapies. It has been suggested that expression of programmed cell death-ligand 1 (PD-L1) in tumours may predict a favourable response to immune checkpoint inhibitors. In order to evaluate the mechanisms of resistance to molecular targeted therapies, immunostaining for PD-L1 is necessary using tumour samples obtained after disease progression. Rebiopsy is performed for this purpose, and TBB seems to be the safest method for doing so, except for cases of skin, muscle or superficial lymph node metastasis. However, the utility of TBB as a rebiopsy method and the impact of...
previous treatment on its diagnostic yield are unknown. Here, we retrospectively evaluated the accuracy and safety of TBB as a rebiopsy method in patients with advanced NSCLC that had relapsed after systemic chemotherapy, and the factors influencing its diagnostic yield.

MATERIALS AND METHODS

Patients
We retrospectively screened 2126 consecutive patients who underwent bronchoscopy at Kurume University Hospital between January 2012 and June 2016. Among these patients, 109 with advanced NSCLC who underwent TBB for rebiopsy after developing resistance to systemic chemotherapy were enrolled. These patients underwent TBB for enrolment in clinical trials that required rebiopsy, further investigation of tumour mutations, or assessment of whether TKI treatment should be continued. In patients who underwent multiple rebiopsies, the result of the initial rebiopsy was selected. The clinical characteristics of the patients, including age, sex, smoking status, histology, mutational status, tumour size, previous treatment and efficacy of the previous treatment, were recorded. Tumour response was examined by CT and evaluated using the Response Evaluation Criteria for Solid Tumors V.1.0 (RESIST V.1.0). The present study was conducted in accordance with the provisions of the Declaration of Helsinki and was approved by the Institutional Review Board of Kurume University Hospital (IRB No. 12029). Informed consent was obtained from the patients.

Procedure of TBB
For TBB, a conventional flexible bronchoscope (BF-260, P260F, P290 or 1T240 Bronchovideoscope, Olympus, Tokyo, Japan) was used after spraying the pharynx with 2% xylocaine. Procedures were performed under conscious sedation with midazolam. TBB was performed under guidance with a radial ultrasound probe (UM-S20-17S, Olympus, Tokyo, Japan) and a guide sheath kit (K-201, Olympus, Tokyo, Japan) was used after spraying the pharynx with 2% xylocaine. Procedures were performed under conscious sedation with midazolam. TBB was performed after first-line treatment in 61 patients, after second-line treatment in 24, and after third-line or further treatment in 24. The mean diameter of the target lesions for rebiopsy was 34.6 mm (range 10–89 mm). Ten patients had lung metastasis that was targeted for rebiopsy. Tumour or bronchial mucosal infiltration was visible on bronchoscopy in 25 patients, and invisible in 84 patients who had only peripheral lung lesions. The overall rate of response to the previous treatment before rebiopsy was 55.0%.

Results of rebiopsy and postprocedural complications
Adequate tumour samples were obtained from 88 patients, giving an overall diagnostic yield of 80.7% (figure 1A). Among these patients with positive diagnostic results, 64 were analysed by predesigned mutational testing and 24 by immunohistochemistry. In 21 patients, the tumour samples collected were inadequate. In 21 patients, the pathological features of the specimens

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Number</th>
<th>Per cent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>33–85</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>50</td>
<td>45.9</td>
</tr>
<tr>
<td>Female</td>
<td>59</td>
<td>54.1</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>59</td>
<td>54.1</td>
</tr>
<tr>
<td>Former/current</td>
<td>50</td>
<td>45.9</td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>101</td>
<td>92.7</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>8</td>
<td>7.3</td>
</tr>
<tr>
<td>Mutational status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGFR</td>
<td>62</td>
<td>56.9</td>
</tr>
<tr>
<td>ALK</td>
<td>5</td>
<td>4.6</td>
</tr>
<tr>
<td>Wild</td>
<td>42</td>
<td>38.5</td>
</tr>
<tr>
<td>Pretreatment line</td>
<td></td>
<td></td>
</tr>
<tr>
<td>First</td>
<td>61</td>
<td>56.0</td>
</tr>
<tr>
<td>Second</td>
<td>24</td>
<td>22.0</td>
</tr>
<tr>
<td>Third or further</td>
<td>24</td>
<td>22.0</td>
</tr>
<tr>
<td>Tumour size (mm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>34.6</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>10–89</td>
<td></td>
</tr>
</tbody>
</table>

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor.
suggested possible malignancy in four patients, these samples were inadequate for mutational analysis or immunostaining because of fragmentation or low numbers of cells. Furthermore, one patient had only a necrotic tissue without viable tumour cells (figure 1B). The specimen from the remaining patients showed normal lung tissue and fibrosis in 13 and 3 patients, respectively (figure 1C).

Post procedural complications were observed in 12 cases. Four patients developed transient fever, and haemorrhage during the biopsy, requiring haemostasis, occurred in eight patients. However, none of these events required inpatient hospitalisation or prolongation of existing hospitalisation. There were no cases of pneumothorax or massive haemoptysis.

Association between diagnostic yield and clinicopathological features

The factors affecting the diagnostic yield of TBB for rebiopsy are shown in table 2. The diagnostic yield of TBB for mass lesions was significantly higher than that for nodular lesions (≥30 mm: 59 of 65 lesions; 90.1% vs <30 mm: 29 of 44 lesions; 65.9%, p<0.01). There was no significant correlation between diagnostic yield and other clinicopathological features including tumour mutational status, previous treatment and efficacy of the previous treatment before rebiopsy.

DISCUSSION

With the development of new therapeutic strategies for NSCLC, including next-generation EGFR-TKIs or blockade of immune checkpoints with monoclonal antibodies, the importance of rebiopsy has increased.11–14 Any method for tissue collection in this setting should be reliable and safe. In the present study, we investigated TBB as a method for rebiopsy in patients with advanced NSCLC that had relapsed after systemic chemotherapy. We found that TBB had a high diagnostic yield of 80.7% and was not associated with severe complications. As far as we are aware, no previous study has investigated the utility of TBB for rebiopsy in NSCLC patients, or the factors influencing its diagnostic yield. Some previous studies have investigated the feasibility of rebiopsy in NSCLC patients. Chouaid et al16 and Bosc et al17 reported that an adequate tissue sample was obtained in 74.4% (61/82) and 89.7% (35/39) of cases, the proportions of patients undergoing TBB for rebiopsy being 52% (43/
82) and 28% (11/39), respectively. Yoon et al. reported a diagnostic yield of 80% (75/94) for chest CT-guided transthoracic lung biopsy, with a postprocedural serious complication rate of 14%. Although the present study was limited to only TBB, the diagnostic yield compared favourably with those of previous studies.

Recently, endobronchial ultrasound-guided TBB with a guide sheath (EBUS-GS) has been used to improve the diagnostic yield for small peripheral pulmonary lesions. Wang Memoli et al. reported the results of a meta-analysis of diagnostic yield for several bronchoscopy modalities. The pooled diagnostic yield was 70% for all modalities, and the highest diagnostic yield for bronchoscopic evaluation (73.2%) appeared to be associated with the use of EBUS-GS. EBUS-GS-guided TBB was also shown to have a quite favourable safety profile, with a pneumothorax rate of 1.5% and no episodes of severe bleeding. Consistent with previous reports, we found that TBB had a high diagnostic yield, even for small peripheral pulmonary lesions, as long as the tumour was detectable by EBUS-GS (figure 2). Furthermore, there were no severe complications such as pneumothorax or serious haemorrhage. In comparison with core needle biopsy or surgical biopsy, which have higher accuracy for rebiopsy but are more invasive, TBB is a safer method with equivalent diagnostic ability.

We initially hypothesised that a dramatic reduction of tumour volume resulting from previous treatment might have a negative impact on the diagnostic yield of TBB. Use of the antiangiogenic agent bevacizumab for non-squamous cell NSCLC and molecular targeting inhibitors for EGFR/ALK-positive NSCLC has yielded relatively high response rates in comparison with conventional systemic chemotherapies. We investigated the association between diagnostic yield and several factors, including the previous treatment regimen or response to the previous treatment before rebiopsy. However, the success of tissue collection by TBB was not associated with tumour mutational status, previous treatment or efficacy of the previous treatment before rebiopsy. Our findings indicated that in a rebiopsy setting, the diagnostic yield and safety profile of TBB are adequate.

This study had several limitations. First, the number of patients included was relatively small. Second, the information was collected retrospectively. Third, the indication of TBB for rebiopsy was determined by individual attending physicians. Also, as TBB was performed for pulmonary lesions considered to have sufficient tissue for biopsy based on CT findings, this may have resulted in selection bias.

In conclusion, we have demonstrated that TBB for rebiopsy of NSCLC that has relapsed after chemotherapy is not associated with severe complications and has a high diagnostic yield, regardless of tumour mutational status, previous treatment or efficacy of the previous treatment before rebiopsy. Our results suggest that TBB is one of the safest and most accurate procedures for rebiopsy, and can yield information useful for decision-making about possible next-line treatment.

**REFERENCES**


**Contributors** HI and KA contributed to the study concept design and drafting of the manuscript. KY, NM, MN, TT, TK and TH contributed to data analysis and interpretation, study design, statistical analysis, and review of the manuscript. All authors had full access to the data of the study, take responsibility for the integrity and accuracy of data analysis, critically reviewed the manuscript, and approved the final version of the manuscript.

**Competing interests** None declared.

**Patient consent** Obtained.

**Ethics approval** The present study was conducted in accordance with the provisions of the Declaration of Helsinki and was approved by the Institutional Review Board of Kurume University Hospital (IRB number 12029).

**Provenance and peer review** Not commissioner; externally peer reviewed.

**Data sharing statement** No additional data are available.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Figure 2. Successful tissue collection in patients with relapse of EGFR-positive adenocarcinoma after EGFR-TKI treatment. (A) Chest CT demonstrates a nodular lesion 12 mm in diameter in S10 of the left lung. (B) EBUS image shows a hypoechoic nodule with an irregular margin. (C) Transbronchial biopsy of the lesion detected by EBUS. EBUS, endobronchial ultrasound; EGFR, epidermal growth factor receptor.


Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy

Hidenobu Ishii, Koichi Azuma, Kazuhiko Yamada, Norikazu Matsuo, Masayuki Nakamura, Takaaki Tokito, Takashi Kinoshita and Tomoaki Hoshino

*BMJ Open Resp Res* 2017 4:
doi: 10.1136/bmjresp-2016-000163

Updated information and services can be found at:
http://bmjopenrespres.bmj.com/content/4/1/e000163

These include:

References
This article cites 29 articles, 3 of which you can access for free at:
http://bmjopenrespres.bmj.com/content/4/1/e000163#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Lung cancer (9)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/